Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
BSC Mouse	NCIT_C14691
Clinical Trial Roles and Responsibilities Matrix	NCIT_C125429	[A document describing the overall management strategy for vendors used to conduct trial-related activities.]
BSCR	NCIT_C14692
Clinical Study Committee Financial Disclosure Form	NCIT_C125422	[A legal document completed by clinical trial independent committee members disclosing any financial arrangement between the member and the sponsor(s) of a clinical study.]
BRVS	NCIT_C14693
Clinical Trial Committe Member Contract	NCIT_C125423	[A written agreement between a clinical trial independent committee member and sponsor or other party that defines any arrangement on delegation and distribution of tasks and obligations.]
Contractual Agreement	NCIT_C115464	[A legally binding accord between two or more people that details any and all arrangements regarding a specific situation(s).]
BRVR Mouse	NCIT_C14694
Clinical Trial Committee Member Confidentiality Disclosure Agreement	NCIT_C125424	[A legally binding document established between the trial sponsor and a clinical trial independent committee member that contains the provisions governing the nondisclosure requirements of any/all information pertaining to the clinical trial.]
European and US Stocks	NCIT_C14695
Clinical Trial Team Training Document	NCIT_C125425	[Documentation attesting to completion of trial team training by the clinical trial sponsor (the pharmaceutical or biotech company).]
NZW	NCIT_C14696
NZM Mouse	NCIT_C14697
NZY	NCIT_C14698
Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes	NCIT_C125420	[A preparation of genetically modified allogeneic T-cells transduced with a replication-incompetent, self-inactivating lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR), comprised of a CD28 co-stimulatory signaling domain fused to CD3 zeta, the single-chain variable fragment of CD123 antigen (interleukin-3 receptor alpha chain or IL3RA), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents recognition of the CAR by Fc receptors (FcRs).]
NZC	NCIT_C14699
Clinical Trial Operational Oversight	NCIT_C125421	[Plans, policies or processes used for clinical trial operations oversight by a sponsor.]
Management	NCIT_C61372	[The act of conducting, controlling or supervising something.]
Electronic Case Report Form Technical Design Document	NCIT_C125437	[Document containing the design elements of the electronic case report form (eCRF) system used in a clinical trial.]
Clinical Trial Patient Database Change Control	NCIT_C125438	[A document, report or log summarizing changes made to a clinical trial patient database. May include the reason for change, relevant approvals, impact/risk analysis, associated requirements, specifications and other documentation describing the validation and implementation of the change.]